Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

blank

 

Recent News and Articles on the Keywords: new neurons + dopamine neurons + parkinson's  Related to the article below (Last Update: 5/13/2008)

Growth Factor Promotes New Neuron Growth in Mouse Model of ...
Newswise (press release) -
Newswise ? Mice induced to develop Parkinson?s disease (PD) show an increase in the growth of new neurons after they are treated with a well known growth ...

The Future of Things
Artificial Stem Cells May Cure Parkinson?s Disease
The Future of Things - May 5, 2008
The transplanted neurons produced dopamine and formed new connections in the rats' brains, compensating for the damage caused by the impaired cells.
Brain-Transplanted Fetal Cells For Parkinson's Treatment May Not ...
eMaxHealth.com, NC - Apr 15, 2008
In addition, the processes that destroy dopamine neurons are not restricted to the midbrain. ?The findings also suggest that there may be either a ...

eFluxMedia
Elevated Urate Levels May Slow Parkinson's in Men
U.S. News & World Report, DC - Apr 14, 2008
Brain scans showed that participants with higher urate levels also lost the fewest dopamine-producing neurons. Parkinson's disease is caused when brain ...
High urate levels seen slowing Parkinson's disease Reuters India
'Elevated urate levels slow progression of Parkinson's' Hindu
Natural Substance Slows Parkinson's InjuryBoard.com
MedPage Today - eMaxHealth.com
all 41 news articles »
Parkinson Transplants Survive At Least 16 Years
Medical News Today (press release), UK - Apr 30, 2008
These are the main findings of a study on grafting of new neurons to the brain in patients with Parkinson's disease. The study, headed by a team of ...
ASNTR awards go to Parkinson's Disease research and patient ...
EurekAlert (press release), DC - May 7, 2008
In recent years, Dr. Carvey has studied factors responsible for converting stem cells into DA neurons and the role played by pro-inflammatory cytokines ...
New discovery may help treat spinal cord injuries, Parkinson's
Hindu, India - Apr 19, 2008
Since dopamine regulates movements and activates those unit burst generators, the next step will be figuring out how dopamine makes individual neurons more ...

TechJournal South
NeoCytex treatment may eventually help regrow brain cells
TechJournal South, NC - Apr 21, 2008
Dopamine is essential for communication with another set of neurons that control motor function. Without it, Parkinson?s patients exhibit tremors and other ...
Staying positive
EastOregonian.info (subscription), OR - Apr 24, 2008
Parkinson's affects neurons in the brain, specifically neurons that make a chemical called dopamine that helps control muscles. ...
Urate Slows Progression of Parkinson's Disease
Medscape (subscription) - Apr 25, 2008
Because oxidative stress may contribute to the loss of dopaminergic neurons in the substantia nigra in patients with PD, the authors postulated that blood ...
Source: Google News

Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease -
CR Freed, PE Greene, RE Breeze, WY Tsai, W … - New England Journal of Medicine, 2001 - content.nejm.org
... stem cells: can old cells learn new tricks?. ... stem cells be a useful source of dopamine
neurons for transplant into patients with Parkinson's disease ...

Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease -
E Hirsch, AM Graybiel, YA Agid - Nature, 1988 - palgrave-journals.com
... of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic
neurons in Parkinson's ... Emson, PC) 427-504 (Raven, New York, 1983 ...

… stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat … -
LM Bjorklund, R Sanchez-Pernaute, S Chung, T … - Proceedings of the National Academy of Sciences, 2002 - National Acad Sciences
... characterized by a loss of midbrain dopamine (DA) neurons ... investigations showing
that fetal DA neurons can produce ... limited the application of this new therapy. ...

Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's -
JH Kim, JM Auerbach, JA Rodr?guez-G?mez, I … - Nature, 2002 - nature.com
... increases the vulnerability of mesencephalic dopamine neurons to MPTP ... model:
Differential effects of dopamine agonists and ... as assessed by a new stepping test. ...

… neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's -
M Levivier, S Przedborski, C Bencsics, UJ Kang - J Neurosci, 1995 - ncbi.nlm.nih.gov
... New York, New York 10032, USA. Parkinson's disease (PD) is a neurodegenerative disorder
characterized by a progressive loss of the dopaminergic neurons of the ...

New dopaminergic neurons in Parkinson's disease striatum -
MJ Porritt, PE Batchelor, AJ Hughes, R Kalnins, GA … - The Lancet, 2000 - Elsevier
... New dopaminergic neurons in Parkinson's disease striatum. ... Summary. A new population
of dopaminergic neurons has been identified in Parkinson's disease striatum. ...

… A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's -
A Hartmann, S Hunot, PP Michel, MP Muriel, S Vyas, … - Proceedings of the National Academy of Sciences, 2000 - National Acad Sciences
... Cognition, and Survival: A NEW ROLE FOR ... in Primary Cultures of Mesencephalic
Dopaminergic Neurons after Neurotoxin ... and Inflammation in Parkinson's Disease Ann. ...

No evidence for new dopaminergic neurons in the adult mammalian substantia nigra -
H Frielingsdorf, K Schwarz, P Brundin, P Mohapel - Proceedings of the National Academy of Sciences, 2004 - National Acad Sciences
... that dopaminergic neurons, the cell type lost in Parkinson's disease, are ... to label
dividing cells, we found no evidence of new dopaminergic neurons in the ...

Predictive Reward Signal of Dopamine Neurons -
W Schultz - Journal of Neurophysiology, 1998 - Am Physiological Soc
... whereas subsequent conditioned stimuli and primary rewards activate dopamine neurons
only transiently while they are uncertain and new contingencies are being ...

Nuclear translocation of NF-kappa B is increased in dopaminergic neurons of patients with Parkinson -
S Hunot, B Brugg, D Ricard, PP Michel, MP Muriel, … - Proceedings of the National Academy of Sciences, 1997 - National Acad Sciences
... Evidence from postmortem studies suggest an involvement of oxidative stress in the
degeneration of dopaminergic neurons in Parkinson disease (PD) that have ...

Source: Google Scholar

The Age of Autism: Anna's last days -- 1

 

On April 26 a Scottish child named Anna Duncan attended a party where two children had chickenpox. Nine days later she got her routine measles-mumps-rubella vaccination. Four days after that she developed classic chickenpox symptoms -- spots and fever.

One week later, on May 14, Anna was dead from an apparent seizure. She was 17 months old.

Now her father, John, is struggling with the sudden loss of a bright, lively child -- and increasingly suspicious that the MMR shot during an apparent chickenpox infection triggered her death.

Those suspicions deepened after he came across Age of Autism's recent investigative series, Pox, which found that giving MMR and chickenpox vaccines at the same time might raise the risk of autism in a susceptible subset of children. By happenstance, the series began the week before Anna's exposure to chickenpox and ended the week after her death.

In Anna's case, Duncan believes the chickenpox she caught at the party suppressed her immune system to the point that the measles virus from the MMR triggered a fatal seizure.

"I feel now that I have an answer to our daughter's death," said Duncan, of Cardrona, Scotland. "What I'm going to try to do with this is force a fatal accident inquiry, because there is a potential scenario here where it could happen again, and if (they) realize that this is a developing story, it can only get bigger."

The Pox series centered on several autistic children in Olympia, Wash., whose families had problematic histories with chickenpox and related herpesviruses. All of the children got the MMR and chickenpox vaccines, in most cases at their 12-month checkups; two of the children were in Merck & Co. clinical trials of investigational chickenpox vaccines in combination with the MMR.

John Duncan said that like the Olympia families, he also had unusual reactions to viral infections and experienced a monthlong outbreak of pox-like spots just after Anna was born. He took photographs at the time to document the spots, which spread diffusely from his abdomen.

"I believe her response to the MMR while infected with chickenpox was due to her genetic makeup from myself," Duncan wrote in a posting on the British Web site jabs.org.uk.

"Anna's normal response to a benign childhood illness, for which recovery was a formality, was interrupted by the MMR vaccine, which due to her understandable immunosuppression resulted in the replication of the measles virus -- 'virus replication,' an accepted and understood medical event in relation to vaccines."

It will be weeks before laboratory tests confirm whether Anna had chickenpox and health authorities rule on cause of death. But authorities in both Britain and the United States assert there is no association between the vaccines and serious health problems. They say the real risk is foregoing vaccinations based on unfounded fears.

The Daily Mail reported in June that "Britain is now in the grip of the biggest measles outbreak since the vaccine's introduction in 1988. Doctors have reported hundreds of cases of measles since January in just three areas of the country, including the death of a 13-year-old boy."

Last week "a group of Britain's leading pediatricians and childhood vaccination experts ... warned that more children will die unless a line is drawn under the autism and MMR vaccine controversy," according to Britain's Guardian newspaper.

"In an open letter, 30 scientists, including some of the country's most eminent child health experts, say that an overwhelming body of evidence shows the vaccine is safe. They add that urgent immunizations are necessary to prevent potentially devastating outbreaks among schoolchildren."

The MMR vaccine Anna received was Priorix, manufactured by GlaxoSmithKline. Chickenpox vaccine is not routinely administered in Britain; in the United States it is recommended by health authorities for all children beginning at age 12 months.

John Duncan provided this sequence of events leading up to Anna's death.

Wednesday, April 26 -- Anna attended the party with her mother, Veronica, where one child was getting over chickenpox and that child's younger sister had all the symptoms of chickenpox.

Friday, May 5 -- Anna got her MMR shot at Haylodge Health Centre, Peebles, Scottish Borders; her mother questioned whether Anna's runny nose and exposure to chickenpox was a cause for concern. The healthcare worker said it was not.

Tuesday, May 9 -- Anna developed signs of chickenpox with spots appearing and a slight fever. This developed into what appeared to be classic chickenpox.

Sunday, May 14 -- Anna died around 9 a.m. with what appeared to be a seizure, with evidence of blood on her lips and on sheets in close proximity to her mouth.

"When Anna had chickenpox we gave her (a fever reducer) to bring her temperature down when it spiked," John Duncan said. "Her temperature according to her mother, who is a nurse, seemed to stabilize on the Saturday night through to Sunday morning, but Anna became restless early on Sunday morning and had two very smelly nappy (diaper) changes. A tired mother put Anna in her cot at around 6 p.m. as she seemed to be more contented on her own.

"Anna's death came as a major shock to us all because at no time did we think that she was going to die. The seizure would have been undetectable in the circumstances. I was with (son) Cameron that morning downstairs because I thought Anna had turned the corner."

Duncan said a doctor who came to the house to confirm the death told his wife it appeared "Anna had chickenpox." She may also have started developing new spots characteristic of measles, he said.

"I would say at time of death there were more measles-like spots appearing around her neck. But I cannot be too sure."

Duncan asked on the Jabs site: "Could this scenario cause autism? Is there a genetic susceptibility in some children to deal with the herpesvirus in a different way to the normal response, making these children more at risk to a bad reaction from MMR at the time of herpes infection? ...

"Had Anna survived her bout of seizure 10 days after her MMR, her brain very possibly could have been damaged and a diagnosis of autism eventually given."

--

Next: Chickenpox and measles -- a troubling combination.

Dopamine Drug Leads to New Neurons and Recovery of Function in Rat Model of Parkinson's Disease

In preliminary results, researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease (PD). The drug also led to long-lasting recovery of function in an animal model of PD. The findings may lead to new ways of treating PD and other neurodegenerative diseases. The study was funded in part by the NIH's National Institute of Neurological Disorders and Stroke (NINDS).

The study suggests that drugs which affect dopamine D3 receptors might trigger new neurons to grow in humans with the disease. Some of these drugs are commonly used to treat PD. The finding also suggests a way to develop new treatments for PD. The results appear in the July 5, 2006, issue of The Journal of Neuroscience.

Parkinson's disease, a progressive neurodegenerative disorder that causes tremors, stiffness, slow movements, and impaired balance and coordination, results from the loss of dopamine-producing neurons in part of the brain called the substantia nigra. While many drugs are available to treat these symptoms during the early stages of the disease, the treatments become less effective with time. There are no treatments proven to slow or halt the course of PD. However, many researchers have been trying to find ways of replacing the lost neurons. One possible way to do this would be to transplant new neurons that are grown from embryonic stem cells or neural progenitor cells. However, this type of treatment is very difficult for technical reasons.

The new study, conducted by Christopher Eckman, Ph.D., and Jackalina Van Kampen, Ph.D., at the Mayo Clinic College of Medicine in Jacksonville, Florida, focused on a second possible way to restore function — prompting stem cells that normally remain dormant in the adult brain to develop into neurons. While most researchers previously believed the adult brain could not develop new neurons, recent studies have shown that the brain contains stem cells and that new neurons can develop in some regions. Studies by Dr. Van Kampen and others also have shown that drugs which affect dopamine D3 receptors can trigger development of new neurons (a process called neurogenesis) in the brains of adult rats. Until now, however, no one had shown that the newly developed neurons could connect with other parts of the brain and restore function.

"This is the first study to show that endogenous neurogenesis [development of new neurons from cells already in the brain] can lead to recovery of function in an animal model of Parkinson's disease," says Dr. Eckman.

The researchers gave either 2-, 4-, or 8-week continuous infusions of a drug called 7-OH-DPAT, which increases the activity of dopamine D3 receptors, into the brain ventricles of adult rats with neuron loss in the substantia nigra and symptoms similar to human PD on one side of the body. 7-OH-DPAT is not used in humans, but its effects on dopamine receptors are similar to the drugs pramipexole and ropinirole, which are approved to treat PD. The rats also received injections of a chemical called bromodeoxyuridine (BrdU), which marks proliferating cells, and infusions of a substance that fluorescently "traces" how neurons connect. The animals were tested before and 3 days after receiving the treatment to see how well they could walk and reach to retrieve food pellets with their paws. A subset of the rats was tested again 2 and 4 months following the treatment.

Rats treated with 7-OH-DPAT had more than twice as many proliferating cells in the substantia nigra as rats that were treated with saline, the researchers found. Many of the newly generated cells appeared to develop into mature neurons, and approximately 28 percent of them appeared to be dopamine neurons by 8 weeks after treatment. Animals treated for 8 weeks also developed almost 75 percent of the normal number of neuronal connections with other parts of the brain and showed an approximately 80 percent improvement in their movements and a significantly improved ability to retrieve food pellets. These effects lasted for at least 4 months after the treatment ended.

"There was a profound behavioral effect of the treatment, even after it 'washed out' of the system," Dr. Eckman notes. "This shows that the treatment affects the underlying pathology."

Several previous studies point to the possibility that drugs like pramipexole and ropinirole might modify the course of PD, but this effect is difficult to test and has never been proven, says Dr. Eckman. While these drugs are useful in treating the symptoms of PD, they have not been designed to prompt development of new neurons, he adds. Altering how the current drugs work or developing new compounds to enhance neurogenesis could provide an entirely new avenue for treating this disease.

“These findings are very exciting for several reasons. Being able to stimulate endogenous stem cells in patients would alleviate the need for transplantation of engineered cells, and as a drug therapy, it would be also easy to administer to patients. Moreover, given that similar drugs exist, medicinal chemistry to maximize this effect could be achieved quickly,” says Diane Murphy, Ph.D., the NINDS program director for the grant that funded this research.

Dr. Eckman and Dr. Van Kampen are now looking at how different doses of pramipexole and similar drugs affect neurogenesis. Once they identify the most effective doses in animals, researchers might be able to test comparable doses in humans. They are also carrying out experiments to learn if using drugs that act on other kinds of receptors might stimulate neurogenesis in Alzheimer's disease and other neurodegenerative diseases.

The NINDS is a component of the National Institutes of Health (NIH) within the Department of Health and Human Services and is the nation’s primary supporter of biomedical research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease. Go to http://www.ninds.nih.gov/ for more information.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


* Van Kampen JM and Eckman CB. "Dopamine D3 Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior." The Journal of Neuroscience, July 5, 2006, Vol. 26, No. 27, pp. 7272-7280.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.